FDA — authorised 17 February 2023
- Application: NDA217171
- Marketing authorisation holder: APELLIS PHARMS
- Local brand name: SYFOVRE
- Indication: SOLUTION — INTRAVITREAL
- Status: approved
🇺🇸 Syfovre™ in United States
FDA authorised Syfovre™ on 17 February 2023
Marketing authorisation
Syfovre™ in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Ophthalmology approved in United States
Frequently asked questions
Is Syfovre™ approved in United States?
Yes. FDA authorised it on 17 February 2023.
Who is the marketing authorisation holder for Syfovre™ in United States?
APELLIS PHARMS holds the US marketing authorisation.